Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROAD trial of delayed-release rifaximin for prevention of recurrent acute diverticulitis
2017-002708-28Phase 2Active
- Sponsor
- Alfasigma
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in diverticulitis and diverticular disease (3 arms), sponsored by Alfasigma. Primary endpoint: Rate of patients with recurrence of diverticulitis or diverticular complications. Started Dec 2017; status: active.
02
Drugs
rifaximin
03
Conditions
diverticulitisdiverticular disease
Beyond the preview
Go deeper on 2017-002708-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002708-28.